Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

Oncolytics Biotech Inc T.ONC

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  ONCY

Oncolytics Biotech, Inc., is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers.
Price: $0.62 | Change: $-0.06 | %Change: -8.82%
Volume: 151,256 | Day High/Low: 0.66/0.62 | 52 Week High/Low: 3.49/0.67


Last Traded: September 29, 2014 11:43 Transaction Volume: 151,256
Open: $0.62 Previous Close: $0.68
Bid: $0.63 Ask: $0.64
Bid Size: 5,000 Ask Size: 11,500
Market Cap: $54.6m Shares Out: 88.1m
PE Ratio: N/A Dividend Yield: N/A
Scale: 1d 5d 3m 6m 1y 2y 5y
Type: Line Area OHLC

Advanced Charts


Canadian Biotech comes back to life: A buyer's guide

Everything you could ever want to know about biotech, biomed and bio investments up north.

Tony Pullen   January 21, 2014
0 stars

Latest Bullboard Posts

  • Target Prices

    0 stars

    Targets are still encouraging.  $1.60, $2.50, $4, etc. Still some optimism out there. Can't really trust analcysts but still... ...

    2.5 stars

  • Selling

    0 stars

    numbers aren't that high but quite a few people are packing it in with ONC. ITG sold 18,000 shares in the final minutes of trading. Not...

    2.5 stars

  • Quick fact about ONC

    0 stars

    Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.05) earnings...

    2 stars

  • ONC - 4.00 PT with a "BUY" rating!!!!!!!!!!!!

    0 stars

    2 stars

  • The sky is not falling chicken little

    0 stars

    Oncolytics did present additional data for a subgroup of patients with a certain gene mutation known as KRAS. In this patient population,...

    2 stars